Reorganizing FDA's structure so disease experts work together may be necessary as Congress and the Obama administration consider agency reforms, but former Commissioner Mark McClellan suggests the status quo is most efficient in some cases.
A proposal from the Friends of Cancer Research would group experts by diseases such as cancer or cardiovascular disorders together and remove FDA's
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?